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The Economic Community of West African States (ECOWAS), which was established by the Lagos Treaty 
of 1975, brings together 15 countries: 
five Anglophones, eight Francophones 
and two Lusophones. The need to 
promote local pharmaceutical industries 
in the region is motivated by a number 
of factors such as high disease burden, 
high cost of imported medicines, growing 
regional market for medicines, expected 
increase in access to anti-retroviral drugs 
and pressure from non-governmental 
organisations.
Currently, there are over 172 local 
pharmaceutical industries, based in 
nine out of 15 West African countries. 
These initiatives have been aimed to 
promote local pharmaceutical industries, 
not only to address the issue of high 
costs of imported medicines but also 
to tap into additional benefits that local 
pharmaceutical industries can bring, such 
as creation of employment opportunities 
and enhancing intra-Africa trade. 
However, there are several bottlenecks 
experienced by the sector, along its value 
chain (access to inputs, manufacturing, 
and marketing). These include:
(a) Access to raw material - over 90% 
of the inputs for local pharmaceutical 
manufacturing is imported i.e. active 
pharmaceutical ingredients (APIs), 
packaging materials, as well as other 
inputs that are not manufactured in the 
region.
(b) Shortage of skilled labour - the human 
resources challenge is not only on 
the number of pharmacists and other 
professionals, but also on their limited or 
non-existent industrial pharmaceutical 
knowledge and skills.
(c) Expensive pharmaceutical 
manufacturing equipment and 
technologies i.e. the bulk of the 
pharmaceutical manufacturing equipment 
are imported, and therefore expensive.
(d) Low investment in pharmaceutical R&D 
in the region.
This policy brief arises from a study 
commissioned by the Scinnovent 
Centre and undertaken by ACTS under 
the auspices of the Science Granting 
Councils Initiative (SGCI).
The study focused on building 
competitive and socially inclusive 
local pharmaceutical industries 
in West Africa and addressed 
five issues: affordability, human 
resources, research and development, 
intellectual property and technology 
transfer.
This policy brief presents findings 
on the human resource situation for 
the pharmaceutical sector in West 
Africa. The policy brief explains the 
current situation and what can be 
done in terms of training, linking 
with diaspora, collaboration and 
partnership with Asian countries 
and building synergy within ECOWAS 
to address the human resource 
requirements for the sector in West 
Africa.
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(e) Medicines regulations in the 
ECOWAS region, member states 
have in place basic legal framework 
for the regulation and control of 
the manufacture, distribution and 
utilisation of medicines for human 
use. 
A review of the systems 
(Anglophone and Francophone) 
showed that medicine regulation 
is still problematic, due to weak 
infrastructure, weak enforcement 
power, and inadequate human 
resource capacity, amongst others. 
The medicines regulatory sector is 
also faced with the problem of poor 
motivation and low retention of staff; 
high levels of counterfeit and illicit 
medicines; and lack of harmonisation 
of medicines regulation. 
There are also differences in 
the requirements for medicines 
registration in member countries.
(f) Accessing market - the local 
manufacturers have problems with 
procurement of pharmaceutical 
products by public agencies as it 
is usually based on the quoted 
price, with a tendency to select the 
lowest bidder. This normally favours 
international pharmaceutical agencies 
over local industries due to the low 
production costs of the former, and 
also all donor and development 
partner-funded procurement of 
essential medicines requires that 
suppliers should have WHO’s product 
prequalification. 
Research and development (R&D) 
play a critical role in the development 
of a vibrant, sustainable and socially 
inclusive local manufacturing 
pharmaceutical industry and can 
enhance affordability of essential 
drugs, productivity, increase 
employment opportunities as well 
reduce dependency on foreign 
support.
Therefore, this policy brief explores 
the impact of R&D on local 
pharmaceutical manufacturing 
industry. It documents the following:
• The status of R&D in the 
pharmaceutical sector, particularly 
in developing pharmaceutical 
materials to support local 
industries. 
• The level of involvement of 
pharmaceutical industries 
on research, innovation and 
development, and the challenges 
they face.
• Existing activities around drug 
development targeting treatment 
of malaria and HIV-AIDS based 
on indigenous knowledge and 
biodiversity. 
• Local production of active 
pharmaceutical ingredients (APIs) 
and what needs to be done to 
jumpstart local production.
APPROACH 
The required information was 
obtained through desk study, 
interviews, and stakeholder’s 
consultations, in five ECOWAS 
countries (Nigeria, Ghana, Cote 
d’Ivoire, Senegal, and Togo) 
undertaken by five national 
consultants, who were contracted in 
each of these countries. In addition, a 
scoping desk study was undertaken on 
Mali, Guinea Conakry, Cape Verde and 
Benin.
In addition to national/in-country 
studies, comparative country 
studies were also used to document 
the differences and similarities in 
approaches between Anglophone and 
Francophone countries on some of 
the issues.
Benchmarking studies were also 
undertaken targeting India, China, 
Brazil, Morocco and Ethiopia, to 
identify some best practices. The 
national consultants prepared national 
reports that were moderated during a 
three-day experience sharing amongst 
the five consultants in Abidjan, Cote 
d’Ivoire. The main findings of this 
study are outlined below:
8http://www.csir.org.gh
RESULTS
1. There are limited Research, 
Innovation and Development 
activities to support pharmaceutical 
industries in the ECOWAS countries.
ECOWAS countries’ universities and 
research organisations have various 
R&D oriented departments/faculties 
within which drug research and 
development are entrenched in the 
following areas - Pharmacognosy, 
Pharmacology, Pharmaceutics, 
Pharmaceutical Technology, Herbal 
Medicine, Industrial Pharmacy and 
Pharmaceutical Chemistry. 
These departments and units conduct 
research in different aspects of drug 
research including development and 
elucidation of active compounds 
from indigenous knowledge and 
biodiversity. For example:
• Nigeria: In 2019, there were 
21 universities in Nigeria 
with faculties of Pharmacy. In 
addition, there are four research 
institutes that stand out with 
mandate in R&D activities relating 
to identification, analysis of 
drugs and development of raw 
materials from local resources 
to the pharmaceutical industry. 
These are: The National Institute 
for Pharmaceutical Research 
and Development (NIPRD), The 
Nigerian Institute of Medical 
Research (NIMR) in Lagos, The 
Raw Materials Research and 
Development Council (RMRDC), 
and the Nigerian Natural Medicine 
Development Agency (NNMDA). 
The parent ministries, mandates 
and thematic areas of activities 
of these pharmaceutical research 
institutions are documented 
(UNIDO, 2011). 
• Ghana: In Ghana, science and 
technology policy development 
issues come under the Council 
for Scientific and Industrial 
Research (CSIR)8. Science and 
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Technology Policy Research 
Institute (STEPRI) and Industrial 
Research Institute (IRI) who are 
directly involved impact on LPP. 
In addition, universities with 
faculties of pharmacy, such as 
Kwame Nkrumah University of 
Science and Technology (KNUST) 
and the University of Ghana (UG) 
also conduct R&D related to the 
pharmaceutical sector.
• Senegal: In Senegal, research 
and development around 
pharmacy takes place at the 
Pharmacy University and 
institutes as Institute of Research 
and Development whereas the 
Institut Pasteur Foundation in 
Dakar is known as one of the 
four producers of yellow fever 
vaccines in the world and the only 
institution in Africa prequalified 
by WHO for the manufacturing of 
yellow fever vaccine. 
• Mali: The Malaria Research Centre 
viewed by many as a model for 
research centre in developing 
countries, as its research is 
planned, directed, and executed 
by African scientists. It also has 
a robust training programme for 
new generation Malian scientists 
critical to the success and 
sustainability of the programme. 
• Côte d’Ivoire: Similarly in Cote 
d’Ivoire, there are several 
universities that undertake 
R&D in medicine. These include 
Université Félix Houphouët-
Boigny; Université d’Abobo-
Adjamé and École de Médecine. 
However, only Felix Houphouey 
Boigny Universite offers training in 
pharmacy and has postgraduate 
programmes where meaningful 
R&D activities in pharmaceutical 
areas take place.
In the health sector, Simpkin et al. 
(2019) identified the three major 
players involved in funding research in 
many African countries as the public 
(government), private sector, and 
international institutions. Currently 
the level of investment of R&D by 
all the West African countries is 
below the 1% of the GDP required. 
According to UNESCO science report 
of 2015, Mali was leading (0.66% in 
2010), followed by Senegal (0.54% in 
2010), Ghana (0.38% in 2010), Togo 
(0.22% in 2012), and Gambia (0.13% 
in 2011). Consequently, many African 
countries rely heavily on research 
grants and/or aids from foreign 
and international organisations. 
Therefore, R&D activities for diseases 
that disproportionately affect African 
countries and address Africa’s unmet 
health needs are poorly funded 
(Gedye, 2013). 
 
2. Involvement of local industries in 
research and development
In West Africa, unlike in many 
developed countries with well-
developed pharmaceutical industries, 
local pharmaceutical industries invest 
very little in R&D. Most of the local 
companies are either subsidiaries 
of foreign companies or operating 
under licensing agreement. In both 
cases, the R&D needs of these local 
industries are met elsewhere. 
The bulk of the rest of the local 
industries do not have adequate 
resources to support their own R&D 
needs, and these needs could be 
met through collaboration with local 
universities. However, this is currently 
difficult due to weak university-
industry linkages in these countries. 
In addition, investment in 
pharmaceutical R&D in many 
African countries by the private 
sector is hampered by unstable 
political environments, weak or 
absent intellectual property laws, 
poor governance, weak regulatory 
structures and corruption (West and 
Schneider, 2017).
3. There are many activities on Drug 
Development based on indigenous 
knowledge and biodiversity
The bulk of research activities taking 
place in West African universities 
and research organisation revolve 
around drug development based 
on indigenous knowledge and 
biodiversity. These are moves in 
the right direction and should be 
supported and encouraged. Below are 
some examples targeting malaria, HIV/
AIDS, sickle cell anaemia and yellow 
fever:
• Ghana: Malaria and HIV/AIDS 
Drug Development based on 
indigenous knowledge. There 
are several herbal preparations 
with crytolepine-based extracts 
in special liquid dosage forms as 
antimalarias on the Ghanaian 
market. Nibima preparations, as 
antimalarias are also products 
from the Centre for Research into 
Plant Medicine[1] at Mampong, 
Akwapim in the Eastern Region. 
• Côte d’Ivoire: According to the 
National Programme for the 
Promotion of Traditional Medicine 
(PNPMT), Kroa Ehoulé, 1,421 
species of medicinal plants used in 
traditional medicine and allowing 
the management of patients have 
been identified to date by Ivorian 
researchers. 
According to PNPMT, in Côte 
d’Ivoire, five million patients are 
monitored and treated each year 
by traditional healers. “Traditional 
medicine does not compete 
with conventional medicine. 
On the contrary, it offers care 
and collaborates with modern 
medicine”. 
In addition, medicinal plants 
are generally used to treat 
malaria, opportunistic infections 
contracted by people living with 
HIV/AIDS, diabetes, hypertension 
and sickle cell disease. PNPMT 
has developed and implemented 
an information and management 
software for traditional health 
practitioners (TPs) to address 
population health issues. The 
software has made it possible 
to identify more than 8,500 
traditional health practitioners in 
12 administrative regions of Côte 
d’Ivoire.
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The West African Health 
Organisation (WAHO) has adopted 
the TPs as a model for identifying 
traditional healers in the sub-
region. As a result, traditional 
medicine has been integrated into 
the Ivorian public health system 
and works alongside conventional 
doctors to take care of patients.
The first pavilion was opened 
recently at the University 
Hospital Centre in Treichville. 
In addition, researchers from 
the University of Bioscience 
and the Pharmacodynamics 
and Biochemistry Laboratory 
have identified and highlighted 
the antimalarial properties of 
plants found in central Côte 
d’Ivoire (Toumodi) and used by 
the people of the Centre for 
malaria treatment. Artemisia 
afra (of African origin) has been 
investigated and is currently 
being used as herbal tea to treat 
malaria.
To date, Artemisia is grown in 
experimental fields, particularly 
in Grand-Bassam, not far from 
Abidjan, but also in the botanical 
garden of the University of 
Korhogo.
• Nigeria: In conjunction with 
the Government, the National 
Institute for Pharmaceutical 
Research and Development 
(NIPRD), initiated and completed 
the research and development of 
a new phytomedicine (Niprisan/
Nicosan) for the management of 
sickle cell anaemia.
The product has been granted 
orphan drug status by the 
United States Food and Drug 
Administration (USFDA) and the 
European Medicine Evaluation 
Agency (EMEA).
The fact that Niprisan/Nicosan 
is the only therapy which will be 
accessible to over 10 million sickle 
cell anaemia patients in sub-
Saharan Africa will give a boost to 
the local pharmaceutical industry 
and NIPRD is now developing 
other phytomedicines for the 
management of prevailing priority 
diseases. 
• Senegal: In addition to research 
performed at the University, 
there is also research carried 
out by UMR VITROME (Mixed 
Research Units: IRD / Aix-Marseille 
University) on malaria. 
This work focuses on three 
main areas: the discovery and 
molecular identification of 
emerging pathogens, the study 
of insect vectors and therapeutic 
research. (Source Mission UMR 
VITROME). Institut Pasteur 
Foundation in Dakar is one of the 
four producers of yellow fever 
vaccine in the world and the only 
one in Africa pre-qualified by 
WHO for the manufacturing of 
yellow fever vaccine.
 This project should therefore 
sustainably strengthen the fight 
against this disease. Scientists 
from the Institut Pasteur, the 
CNRS and Sanofi Pasteur have 
recently developed a novel 
alternative method to animal 
testing that can be used to verify 
the safety of vaccines such as the 
yellow fever vaccine. 
In addition, Senegal has a rich 
experience in medicinal plants 
and has some traditional medicine 
centres and Community Centre 
for Appropriate Technologies 
for Health (CCTAS). Senegal 
has established by ministerial 
decree a National Commission 
for Senegalese Traditional 
Pharmacopoeia and the National 
Formulary. 
This commission aims to develop 
the Senegalese pharmacopoeia 
and the national form. Regulatory 
texts relating to the registration 
of improved traditional medicines 
(MTAs) have been also developed. 
The updating of these documents 
and their adoption will allow the 
development of MTAs. Today, 
traditional healers need scientific 
supervision to guarantee the 
safety of MTAs. For this purpose, 
centres of clinical experimentation 
of medicinal plants have been 
created in the health centre but 
they are not functional due to lack 
of operating budgets. (Source PNP 
2014).
• Mali: Malaria Research Centre 
currently conducts research 
around vaccines, diagnostics, 
immunology and genetics, and 
prevention. 
Mali Traditional Medicines 
established in 1973 is the 
official institute connected 
to the National Institute of 
Research in Public Health and 
the main activities it is engaged 
in are; registration of traditional 
practitioners, medicinal plants, 
research and development of 
Improved Traditional Medicines.
4. Local production of Active 
Pharmaceutical Ingredients (APIs) 
and other inputs for pharmaceutical 
industries
Production of active pharmaceutical 
ingredients
Local production of active 
pharmaceutical ingredients (APIs) is 
key to the growth and development 
of the pharmaceutical industry in 
ECOWAS. This is because the region 
imports 95% of their requirements 
as inputs for local production. API 
production is capital intensive and 
the technology involved is also 
relatively expensive and sophisticated. 
Internationally, API production is 
shifting to China and India. Relatively 
few companies have been involved in 
the production of APIs in West Africa.
Ghana-based Lagray Chemical 
Company Limited was the first 
vertically integrated generic 
pharmaceutical manufacturer in 
West Africa. They were involved in 
the development, manufacture, and 
marketing of APIs. Lagray produced 
the API erythromycin, which was 
used as an intermediary for the 
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production of Azithromycin. Lagray 
fully utilised the API they produced 
as an intermediary and none was 
offered for sales to other companies. 
From all indications, the volumes 
of the API produced were not that 
high and the company folded due 
to low revenue generation and 
mobilisation. The company’s products 
were mostly second and third line 
products for treatment and the 
necessary prescription traction could 
not be generated in the Ghana Health 
System. 
The local production of APIs has 
been hampered by factors like weak 
or absent intellectual property 
laws, poor governance structures, 
weak regulatory structures, lack of 
transparency (corruption), inadequate 
funding, lack of incentives to support 
R&D, lack of collaboration between 
academia and industries, and 
instability of government policies.
Local production of other inputs for 
the pharmaceutical sector
The Nigerian National Institute 
for Pharmaceutical Research and 
Development (NIPRD) has carried 
out research and development 
into pharmaceutical grade starch 
as it would be most advantageous 
to local drug manufacturers if 
starch could be processed locally 
to produce pharmaceutical grade 
starch; pre-gelatinised starch used as 
pharmaceutical binder; and dextrose 
monohydrate marketed as glucose 
powder (nutraceuticals), which is 




With reference to the above findings 
of the study, the following conclusions 
and recommendations are worthwhile 
considering: 
• Currently the impact of 
research institutions on local 
pharmaceutical production 
is minimal due to inadequate 
funding and the low demand for 
R&D by local industries. There 
is need to increase funding, 
particularly those related to 
alternative local sources of inputs 
for the pharmaceutical sector.
• Plenty of effort has been made 
towards drug development 
based on the local indigenous 
knowledge and biodiversity 
especially in Cote d’Ivoire and 
Senegal to curb malaria and HIV/ 
AIDS challenges. These efforts 
should be strengthened and 
supported.
• There should be a national 
database and an integrated 
regional database for the 
traditional healers in the region, 
and policies formulated on 
integrating them in the national 
and regional R&D system.
• The current practice of integrating 
the local/ traditional medicines 
with the conventional ones 
in hospitals for treatment of 
patients in some countries is 
commendable and should be 
adopted by other countries in 
the region and beyond. Policy 
makers can influence this 
through establishment of the 
right legislative and regulatory 
frameworks.
• The involvement of local 
pharmaceutical industries 
in research is minimal and 
collaboration between local 
pharmaceutical industries 
and universities and research 
organisations in the region 
for R&D is negligible. There 
is also need to provide local 
pharmaceutical industries with 
incentives (tax) on R&D works and 
capital investment in research 
and development projects in the 
region.  Funding of joint research 
undertaken by universities and 
industries in the sector should 
also be encouraged. 
• The level of involvement of 
research organisations in 
the pharmaceutical sector 
conducting research, innovation 
and development is growing 
but it still lacks the capacity and 
right capability for effective and 
efficient identification, analysis 
of drugs and development of raw 
materials for the local industries. 
The high cost of equipment, 
high level of professional skills 
and expertise required are also 
contributing factors. Hence we 
recommend tax exemptions or tax 
incentives on importation of these 
equipment and raw materials for 
the industry.
• Production/manufacturing of 
active pharmaceutical ingredients 
in the region is hampered by low 
volumes, high cost of production 
and low revenue generation 
and mobilisation. To make the 
production of APIs more feasible, 
there should be tax exemption on 
APIs raw material imports, and 
tax incentives for investment in 
local pharmaceutical industries. 
It is also considered that local 
industries and R&D organisations 
have a better chance of producing 
API based on local products.
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